Global Biosimilars Partnership Report / Directory 2021: Access Conditions and Agreements for Over 170 Offers 2010-2021 – ResearchAndMarkets.com
DUBLIN – (BUSINESS WIRE) – The report “Global Biosimilars Partnering Terms and Agreements 2010 to 2021” has been added to ResearchAndMarkets.com offer.
The Global Biosimilars Partnering Terms and Agreements 2010 to 2021 report provides an understanding and access to the biosimilars agreements and partnership agreements entered into by the world’s leading healthcare companies.
The report provides a detailed understanding and analysis of how and why companies enter into partnership agreements with biosimilars. The majority of agreements are at an early stage of development where the licensee obtains a right or option right to license the biosimilar technology or product candidates from the licensor. These agreements tend to be multi-component, starting with collaborative R&D and the commercialization of results.
Understanding the flexibility of the terms of the agreements negotiated by a potential partner provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of the terms. While many small businesses will be looking for details on payment terms, the devil is in the details of triggering payments – contract documents provide that insight where press releases and databases do not. .
This report contains links to online copies of actual biosimilar offerings and contractual documents as submitted to the Securities Exchange Commission by the companies and their partners. Contract documents provide the answers to many questions about a potential partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the agreement.
Contract documents provide the answers to many questions about a potential partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the agreement.
In addition, a comprehensive appendix is provided, curated by biosimilar partner company AZ, transaction type definitions and examples of biosimilar partnership agreements. Each transaction title is linked via a web link to an online version of the transaction record and, if applicable, the contractual document, providing easy access to each contractual document on demand.
The report also includes numerous tables and figures that illustrate trends and biosimilar partnership and negotiation activities since 2010.
In conclusion, this report provides everything a potential negotiator needs to know about partnering in the research, development and commercialization of biosimilar technologies and products.
Scope of the report
The terms and global partnership agreements for biosimilars 2010 to 2021 include:
Trends in biosimilar transactions in the biopharmaceutical industry since 2010
Access to title, advance, milestone and royalty data
Access to more than 170 transaction files and contractual documents on biosimilars, where applicable
The main biosimilar offers by value since 2010
The most active biosimilars negotiators since 2010
The main partnership resources for biosimilars
In Global Biosimilars Partnering Terms and Agreements 2010 to 2021, the available contracts are listed by:
Company from A to Z
Title value
Stage of development at signing
Component type of the agreement
Specific therapeutic and technological target
Main topics covered:
Abstract
Chapter 1 Introduction
Chapter 2 – Trends in the negotiation of biosimilars
2.1. introduction
2.2. Biosimilar partnerships over the years
2.3. The most active biosimilars negotiators
2.4. Biosimilar partnerships by type of agreement
2.5. Biosimilar partnership by therapeutic area
2.6. Terms of the agreement for the biosimilar partnership
2.6.1 Key values of the partnership on biosimilars
2.6.2 Biosimilars Process Upfront Payments
2.6.3 Milestone Payments for Biosimilars
2.6.4 Biosimilar royalty rate
Chapter 3 – Best Biosimilar Offers
3.1. introduction
3.2. Best Biosimilar Deals By Value
Chapter 4 – The Most Active Biosimilars Negotiators
4.1. introduction
4.2. The most active biosimilars negotiators
4.3. Profiles of the most active biosimilar partner companies
Chapter 5 – Negotiation directory for biosimilars contracts
5.1. introduction
5.2. Directory of biosimilar contracts
Chapter 6 – Biosimilar Transactions by Type of Technology
Chapter 7 – Partner Resource Center
7.1. Online partnership
7.2. Partnership events
7.3. Further reading on negotiation
Appendices
Annex 1 – Biosimilar offers by AZ company
Annex 2 – Biosimilar offers by stage of development
Annex 3 – Biosimilar offers by type of offer
Annex 4 – Biosimilar offers by therapeutic area
Annex 5 – Definitions of types of transactions
Companies mentioned
BeiGene
Momenta Pharmaceuticals
Ewopharma
Samsung Bioepis
Biotechnology compass
YL organic products
alvogen
Simcere Pharma
Medicago
Cipla
Merck serono
JAMP Pharma Group
Yoshindo
SQI diagnosis
R-Pharm
Sandoz
ProBioGen
Diabeloop
Biocnd
Epirus Biopharmaceuticals
mAbXience
AIT Biosciences
Concord Biosciences
Abreos Biosciences
Revance Therapeutics
Walter and Eliza Hall Institute
Zhejiang Hisun Pharmaceutical
TS Dyne
Amneal Pharmaceuticals
MGC diagnosis
Theradiag
XL-Protein
Aceno Biotherapeutics
Baxter International
Zhejiang Huahai Pharmaceutical
BioXpress
Pharma Holdings algorithm
World-class research
PharmaPraxis
GC Pharma
Universal cells
Synthon
Chimio Sa Lugano
Amgen
Return-To-Line
Vela Laboratories
NeuClone
Cellectis
TR-Pharm
For more information on this report, visit https://www.researchandmarkets.com/r/krrkae
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Director
press@researchandmarkets.com
For EST office hours, call 1-917-300-0470
For USA / CAN call toll free 1-800-526-8630
For GMT office hours, call + 353-1-416-8900
Comments are closed.